Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fei, Xiang | - |
dc.contributor.author | Jung, Sooyun | - |
dc.contributor.author | Kwon, Sangil | - |
dc.contributor.author | Kim, Jiweon | - |
dc.contributor.author | Corson, Timothy W. | - |
dc.contributor.author | Seo, Seung-Yong | - |
dc.date.accessioned | 2024-07-18T10:00:17Z | - |
dc.date.available | 2024-07-18T10:00:17Z | - |
dc.date.issued | 2024-06 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/92016 | - |
dc.description.abstract | Age-related macular degeneration (AMD) is the leading cause of vision loss in senior adults. The disease can be categorized into two types: wet AMD and dry AMD. Wet AMD, also known as exudative or neovascular AMD, is less common but more severe than dry AMD and is responsible for 90% of the visual impairment caused by AMD and affects 20 million people worldwide. Current treatment options mainly involve biologics that inhibit the vascular endothelial growth factor or complement pathways. However, these treatments have limitations such as high cost, injection-related risks, and limited efficacy. Therefore, new therapeutic targets and strategies have been explored to improve the outcomes of patients with AMD. A promising approach is the use of small-molecule drugs that modulate different factors involved in AMD pathogenesis, such as tyrosine kinases and integrins. Small-molecule drugs offer advantages, such as oral administration, low cost, good penetration, and increased specificity for the treatment of wet and dry AMD. This review summarizes the current status and prospects of small-molecule drugs for the treatment of wet AMD. These advances are expected to support the development of effective and targeted treatments for patients with AMD. | - |
dc.format.extent | 20 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration | - |
dc.type | Article | - |
dc.identifier.wosid | 001251991900001 | - |
dc.identifier.doi | 10.1007/s12272-024-01503-3 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.47, no.6, pp 538 - 557 | - |
dc.identifier.kciid | ART003100468 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85196414836 | - |
dc.citation.endPage | 557 | - |
dc.citation.startPage | 538 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 47 | - |
dc.citation.number | 6 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Age-related macular degeneration | - |
dc.subject.keywordAuthor | Small-molecule | - |
dc.subject.keywordAuthor | Vascular endothelial growth factor | - |
dc.subject.keywordAuthor | RTK inhibitors | - |
dc.subject.keywordAuthor | Integrin inhibitors | - |
dc.subject.keywordAuthor | Complement inhibitors | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | SOLUBLE EPOXIDE HYDROLASE | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | CHOROIDAL NEOVASCULARIZATION | - |
dc.subject.keywordPlus | KINASE INHIBITOR | - |
dc.subject.keywordPlus | INTRAVITREAL INJECTION | - |
dc.subject.keywordPlus | THERAPEUTIC TARGET | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | PALOMID 529 | - |
dc.subject.keywordPlus | VEGF | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.